Exelon

rivastigmine

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Exelon. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exelon.

What is Exelon?

Exelon is a medicine containing the active substance rivastigmine. It is available as capsules (1.5, 3, 4.5 and 6 mg), as an oral solution (2 mg/ml), and as transdermal patches, which release either 4.6, 9.5 or 13.3 mg rivastigmine across the skin over 24 hours.

What is Exelon used for?

Exelon is used for the treatment of patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.

The capsules and oral solution can also be used to treat mild to moderately severe dementia in patients with Parkinson’s disease.

The medicine can only be obtained with a prescription.

How is Exelon used?

Treatment with Exelon should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease. Treatment should only be started if a caregiver is available who will regularly give and monitor the use of Exelon by the patient. Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.

Exelon capsules or oral solution should be given twice a day, with morning and evening meals. The capsules should be swallowed whole. The starting dose is 1.5 mg twice a day. In patients who tolerate this dose, it can be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day. The highest tolerated dose should be used to get the maximum benefit, but the dose should not exceed 6 mg twice a day.

If the transdermal patches are used, the 4.6-mg-per-24-hours patch should be used first, with the dose increased to the 9.5-mg/24-h patch after at least four weeks if the lower dose is well tolerated. The 9.5-mg/24-h patch should be used for as long as the patient benefits from it. After six months of treatment with 9.5 mg/24 hours, the doctor may increase the dose to 13.3 mg/24 hours if the patient’s condition has worsened. The patches are applied to clean, dry, hairless, intact skin on the back, upper arm or chest, and are replaced every 24 hours. They should not be placed on irritated or red skin, on the thigh or abdomen (tummy), or in places where they will be rubbed by tight clothing. The patches can be worn during bathing and hot weather. The patches should not be cut into pieces. Patients can be switched from the capsules or oral solution to the patches. See the summary of product characteristics (also part of the EPAR) for detailed information.

How does Exelon work?

The active substance in Exelon, rivastigmine, is an antidementia medicine. In patients with Alzheimer’s dementia or dementia due to Parkinson’s disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). 

Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Exelon allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia associated with Parkinson’s disease.

How has Exelon been studied?

Exelon has been studied in mild to moderately severe Alzheimer’s disease. The capsules have been studied in 2,126 patients in three main studies, and the transdermal patches in one main study involving 1,195 patients. Exelon capsules have also been studied in 541 patients with dementia due to Parkinson’s disease. All of the studies lasted six months and compared the effects of Exelon with those of placebo (a dummy treatment). The main measures of effectiveness were the change in symptoms in two main areas: cognitive (the ability to think, learn and remember) and global (a combination of several areas including general function, cognitive symptoms, behaviour and the ability to carry out everyday activities).

An additional study in 27 patients was used to show that Exelon capsules and oral solution produced similar levels of the active substance in the blood.

What benefit has Exelon shown during the studies?

Exelon was more effective than placebo at controlling symptoms. In the three studies of Exelon capsules in patients with Alzheimer’s dementia, patients taking doses of Exelon between 6 and 9 mg per day had an average increase in cognitive symptoms of 0.2 points from a baseline of 22.9 points at the start of the study, where a lower score indicates better performance. This was compared with an increase of 2.6 points from 22.5 in the patients taking placebo. For the global score, patients taking Exelon capsules had in increase in symptoms of 4.1 points, compared with 4.4 in those taking placebo. The Exelon transdermal patches were also more effective than placebo in preventing dementia from getting worse.

The patients with dementia due to Parkinson’s disease taking Exelon capsules showed an improvement in cognitive symptoms of 2.1 points, compared with a worsening of 0.7 points in those taking placebo, from a baseline of around 24 points. The global symptom score also improved more in the patients taking Exelon.

What is the risk associated with Exelon?

The types of side effects seen with Exelon depend on the type of dementia it is being used to treat and whether the capsules, oral solution or transdermal patches are used. Overall, the most common side effects (seen in more than 1 patient in 10) include nausea (feeling sick) and vomiting, particularly during the phase when the dose of Exelon is being increased. For the transdermal patch, application site reactions are the most commonly seen side effects. For the full list of all side effects reported with Exelon, see the package leaflet.

Exelon must not be used in people who are hypersensitive (allergic) to rivastigmine, other carbamate derivatives or any of the other ingredients. Exelon must also not be used in patients who are suspected to have had a severe allergic reaction called ‘allergic contact dermatitis’ to the Exelon patch in the past.

Why has Exelon been approved?

The CHMP concluded that Exelon has a modest effectiveness in treating the symptoms of Alzheimer’s dementia, although this does reflect an important benefit in some patients. The Committee initially concluded that for the treatment of dementia due to Parkinson’s disease, Exelon’s benefits did not outweigh its risks. However, following a re-examination of this opinion, the Committee concluded that the medicine’s modest effectiveness could also be of benefit to some of these patients. Therefore, the Committee decided that Exelon’s benefits are greater than its risks and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe use of Exelon?

The company that makes Exelon must ensure that all doctors who intend to prescribe the Exelon 13.3-mg/24-h transdermal patch receive an information pack containing instructions to be given to patients and caregivers on how to use the patch safely as well as a reminder card for patients and caregivers that contains key information on how to use the patch and allows them to record the application and removal of patches.

Other information about Exelon

The European Commission granted a marketing authorisation valid throughout the European Union for Exelon on 12 May 1998.

For more information about treatment with Exelon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Exelon : EPAR - Summary for the public BG = bălgarski 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public ES = español 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public CS = čeština 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public DA = dansk 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public DE = Deutsch 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public ET = eesti keel 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public EL = elliniká 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public EN = English 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public FR = français 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public IT = italiano 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public LV = latviešu valoda 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public LT = lietuvių kalba 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public HU = magyar 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public MT = Malti 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public NL = Nederlands 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public PL = polski 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public PT = português 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public RO = română 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public SK = slovenčina 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public SL = slovenščina 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public FI = suomi 16/06/2006 06/02/2013
Exelon : EPAR - Summary for the public SV = svenska 16/06/2006 06/02/2013

This EPAR was last updated on 14/01/2016 .

Authorisation details

Product details

Product details for Exelon
NameExelon
Agency product numberEMEA/H/C/000169
Active substance

rivastigmine

International non-proprietary name (INN) or common name

rivastigmine

Therapeutic area DementiaParkinson DiseaseAlzheimer Disease
Anatomical therapeutic chemical (ATC) code N06DA03

Publication details

Publication details for Exelon
Marketing-authorisation holder

Novartis Europharm Ltd

Revision35
Date of issue of marketing authorisation valid throughout the European Union12/05/1998

Contact address:

Novartis Europharm Ltd
Frimley Business Park
Camberley GU16 7SR
United Kingdom

Product information

Product information

19/11/2015  Exelon -EMEA/H/C/000169 -PSUSA/2654/201501

Name Language First published Last updated
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016
Exelon : EPAR - Product Information SV = svenska 13/02/2009 14/01/2016

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013
Exelon : EPAR - All Authorised presentations SV = svenska 21/11/2007 12/06/2013

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Exelon : EPAR - Procedural steps taken before authorisation SV = svenska 12/01/2006  
Exelon : EPAR - Scientific Discussion SV = svenska 12/01/2006